INmune Bio Inc (INMB) 1.26 USD (-6.67%) | Healthcare NASDAQ

INmune Bio Inc is a biotechnology company focused on developing immunotherapeutic treatments for cancer and inflammatory diseases.

biotechnology oncology

Comment

Performance & Momentum

6 Months 9.90 %

1 Year 80.89 %

3 Years 82.08 %

5 Years 89.45 %

Momentum

Unlock this indicator

Recent News

INmune Bio Inc

INmune Bio Launches $19M At-the-Market Sale

11 months ago

On June 27, 2025, INmune Bio announced a $19 million capital raise through an at-the-market offering, mainly to healthcare investors. The move is aimed at strengthening the clinical-stage company’s cash position, without causing significant immediate dilution for shareholders. The market reaction has been steady despite the news, with the stock trading around -0.72%, suggesting investors remain neutral for now.

source: globenewswire.com • fundraising, biotechnology

Strategic Analysis

INmune Bio Inc is positioned in biotechnology through the development of innovative immunotherapies primarily targeting cancers and inflammatory diseases. Its business model is based on advanced research in immuno-oncology, focusing on a niche with strong therapeutic potential but one that is highly competitive and risky.

Strengths

Specific focus on immunotherapy, a rapidly expanding medical field.
Expertise in oncology and inflammatory diseases, offering opportunities for differentiated treatments.

Weaknesses

Severe and persistent stock underperformance indicating elevated risk and a lack of recent clinical validation.
Lack of recent news suggesting limited operational or communications momentum.

Momentum

Momentum is very weak, reflecting a context of strong selling pressure and market skepticism. This trend underscores the need for a significant clinical advance to restore investor confidence.

Analysis performed 1 month ago